Regulus Therapeutics Q1 EPS $(0.15) Beats $(0.24) Estimate

Regulus Therapeutics (NASDAQ: RGLS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.24) by 37.5 percent. This is a 48.28 percent increase over losses of $(0.29) per share from the same period last year.